Navigation Links
NYP/Weill Cornell physician-scientists present latest cancer findings at ASCO meeting
Date:5/31/2008

NEW YORK (May 29, 2008) -- Leading oncologists and cancer researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center are presenting new basic and clinical research findings at the 44th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, May 30 to June 3.

Highlights from the symposium presentations and posters to be made by NewYork-Presbyterian/Weill Cornell physician-scientists include the following:

Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 in patients with metastatic castrate-resistant prostate cancer. [Abstract number: 5140; Poster number: 13H]

Time: Saturday, May 31. 8:00 a.m. 12:00 p.m.
Authors: S. T. Tagawa, M. I. Milowsky, M. J. Morris, S. Vallabhajosula, S. Goldsmith, D. Matulich, J. Kaplan, F. Berger, H. I. Scher, N. H. Bander, D. M. Nanus

Drs. Scott Tagawa, Neil Bander and their colleagues at NewYork-Presbyterian/Weill Cornell will present data from a Phase II clinical trial showing that a monoclonal antibody designated "J591," carrying a payload of a radioactive isotope (177Lu), is both safe and effective in the treatment of late-stage metastatic prostate cancer. The antibody works by targeting only prostate cancer cells anywhere in the body while leaving the healthy cells around them unharmed. Patients in this trial had progressing, hormone-independent, metastatic prostate cancer with rapidly increasing prostate specific antigen (PSA) levels. Following only one dose of the J591 antibody loaded with the maximum radiation dose, PSA levels fell in two-thirds of patients with half of all the patients achieving a significant threshold of at least a 30-percent PSA decline. The 30-percent PSA decline threshold has been shown in two large, independent registration trials to be the best PSA surrogate for survival benefit. Additionally, the clinician-scientists found that none of the patients developed symptomatic side effects as a result of the radioactive antibody drug. Currently, two other monoclonal antibodies carrying a radioactive payload are FDA approved, both for the treatment of non-Hodgkins' lymphoma. The researchers are expanding their clinical trials to include earlier stage patients who are more likely to respond, and expanding the trials to other centers around the country.

A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC).

Oral Presentation; [Abstract number: 5502; Location: S406 (Vista Room)]

Time: Sunday, June 1, 5:30 p.m. 5:45 p.m.
Authors: B. M. Slomovitz, K. H. Lu, T. Johnston, M. Munsell, L. M. Ramondetta, R. R. Broaddus, R. L. Coleman, C. Walker, D. M. Gershenson, T. W. Burke, J. Wolf

Dr. Brian Slomovitz will present results from a Phase II clinical trial (during an oral presentation) showing that the orally administered experimental drug RAD001, a mammalian target of rapamycin (mTOR) inhibitor, is beneficial in patients with recurrent endometrial cancer. The drug blocks the activity of the mTOR protein within the cytoplasm of cancer cells, responsible for cancer cell proliferation and growth. The physician-scientists found that the drug slowed cancer progression in 44 percent of subjects in the study. The study was conducted in collaboration with the MD Anderson Cancer Center.

Preoperative treatment with pazopanib (GW786034), a multikinase angiogenesis inhibitor in early-stage non-small cell lung cancer (NSCLC): A proof-of-concept phase II study. [Abstract number: 7557; Poster number 34G]

Time: Sunday, June 1, 2:00 p.m. 6:00 p.m.
Authors: N. Altorki, M. Guarino, P. Lee, H. I. Pass, E. Filip, T. Bauer, D. Roychowdhury, T. Zaks, L. Ottesen, D. Yankelevitz

Dr. Nasser Altorki will present final data from a Phase II clinical trial showing that a drug that stops blood vessel growth (angiogenesis) to tumors is safe and highly effective for the treatment of early-stage non-small cell lung cancer. Pazopanib works by blocking the action of vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which both work by growing bloods vessels that supply nutrition to tumors. Prior to surgery to remove their tumors, 87 percent of the 26 subjects tested had a significant reduction in tumor growth.

Palonosetron (PALO) for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose melphalan prior to stem cell transplant (SCT). [Abstract number: 9617; Poster number 47B]

Time: Saturday, May 31, 2:00 p.m. 6:00 p.m
Authors: S. Giralt, K. Mangan, R. Maziarz, J. S. Bubalo, R. Beveridge, D. D. Hurd, F. Mendoza, E. B. Rubenstein, T. J. DeGroot, M. W. Schuster

Principal investigator Dr. Michael Schuster's multicenter trial group will present findings from a Phase II clinical trial showing that a new drug called Palonosetron (PALO) is safe and effective at reducing vomiting and nausea -- common side effects of chemotherapy -- in multiple myeloma patients undergoing multi-day high-dose chemotherapy and autologous stem cell transplantation. All of the subjects studied were taking a common chemotherapy agent called melphalan at the time of the study. The researchers found that those who were on multiple daily doses of PALO reported fewer incidences of vomiting and nausea.

LE-SN38 for metastatic colorectal cancer after progression on oxaliplatin: Results of CALGB 80402. [Abstract number: 4109; Poster number: 16A]

Time: Monday, June 2, 8:00 a.m. 12:00 p.m.
Authors: A. J. Ocean, D. Niedzwiecki, J. N. Atkins, B. Parker, B. H. O'Neil, J. W. Lee, S. Wadler, R. M. Goldberg

Dr. Allyson Ocean will present data showing that LESN-38, the active molecule of the chemotherapy drug irinotecan, did not have benefit in slowing the progression of metastatic colorectal cancer. The drug was reformulated and packaged into a liposome, a spherical molecule resembling a bubble made from lipid (fat) molecules, for delivery into the body, with the hope of reducing common side effects of chemotherapy. However, while the results for reduced toxicity are promising, the findings show that the drug did not slow cancer progression at the dose and formulation tested in this trial.


'/>"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Related medicine news :

1. NYP/Weill Cornell gene therapy clinical trial yields promising results for Batten disease
2. NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration
3. Healthy restaurants help make us fat, says a new Cornell study
4. The latest about male infertility and testosterone from NewYork-Presbyterian/Weill Cornell
5. White House awards Weill Cornells Bruce McCandliss highest honor for early career scientists
6. Weill Cornell receives $2.4 million in grants from Gates Foundation to fight tuberculosis
7. NewYork-Presbyterian/Weill Cornell creates world-class cancer center
8. By color-coding atoms, new Cornell electron microscope promises big advance in materials analysis
9. $50 million gift to NewYork-Presbyterian Hospital/Weill Cornell Medical Center
10. Weill Cornell team identifies potential new drug targets against hormone-dependent breast cancer
11. Weill Cornell receives funding to study creation of new elder abuse center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... ... and pharmaceutical organizations to build intelligent, connected applications, was named the best Sales ... , The winner announcement was made today by the Software & Information ...
(Date:12/2/2016)... ... December 02, 2016 , ... ‘Tis the season for giving! Today, 20 ... the National Family Partnership and the Drug Enforcement Administration as part of the National ... the 10 winning schools who decorated their campuses with this year’s Red Ribbon Week ...
(Date:11/30/2016)... Northridge, CA (PRWEB) , ... November 30, 2016 ... ... Elyson, announce that they now offer a comprehensive in-house dental plan for all ... dentists have developed a plan that gives patients a number of perks, including ...
(Date:11/30/2016)... PALMYRA, Wisconsin (PRWEB) , ... November 30, 2016 ... ... inclusion in the 2016 Deloitte Wisconsin 75, an annual ranking and recognition of ... consecutive year on the list, having ranked from 2008-2016. In addition, Standard Process ...
(Date:11/30/2016)... Chino Hills, CA (PRWEB) , ... November 30, ... ... in eating disorder and mental health treatment has announced the opening of a ... specialized residential treatment for girls with mental health issues such as severe anxiety, ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... FRANCISCO , Dec. 2, 2016  PipelineRx, a ... telepharmacy, will be offering demonstrations of its SaaS-based ... Society of Health-System Pharmacists 2016 Midyear Clinical Meeting ... Vegas . With nearly 300 hospital clients ... services and technology designed to dramatically improve pharmacy ...
(Date:12/2/2016)... December 2, 2016 On Thursday, ... honored excellence in research, development and innovation in the ... dinner was held in the presence of Sergey Tsyb, ... Russian Federation , Natalia Sanina, First Vice ... Murashko , Head of Roszdravnadzor, National Service of Control ...
(Date:12/2/2016)...  Eli Lilly and Company (NYSE: LLY ... provide updated financial guidance for 2016 on Thursday, December ... on that day with the investment community and media ... The conference call will begin at 10 a.m. ET. ... live webcast of the conference call through a link ...
Breaking Medicine Technology: